房颤相关缺血性卒中紧急再灌注后抗凝安全性
本研究合并RAF与RAF-NOACs两项前瞻性观察研究,纳入2159例房颤相关急性缺血性卒中患者,其中564例接受紧急再灌注治疗。90天主要复合结局在再灌注组为7%、未再灌注组为9%(OR 0.74,95%CI 0.50-1.07),倾向评分匹配后两组风险相当(OR 1.06,95%CI 0.53-2.02),提示紧急再灌注不影响启动口服抗凝后的早期复发与出血风险。
要点
- 房颤相关卒中紧急再灌注后启动口服抗凝,90天主要结局风险与未再灌注者相当。
- 再灌注组与未再灌注组启动抗凝的中位时间分别为7.5天与7.0天。
- 倾向评分匹配后主要结局OR 1.06(95%CI 0.53-2.02),未见显著差异。
核心结论
- 紧急再灌注治疗未影响房颤相关急性缺血性卒中患者启动口服抗凝后早期复发和主要出血的风险。
研究设计与样本
- 合并RAF与RAF-NOACs两项前瞻性观察研究数据,纳入2012年1月至2016年6月连续房颤相关急性缺血性卒中患者,共2159例,其中564例(26%)接受紧急再灌注治疗。
主要发现
- 90天主要复合结局在再灌注组为37例(7%),未再灌注组为146例(9%),OR 0.74(95%CI 0.50-1.07)。
- 倾向评分匹配后两组主要结局风险相当,OR 1.06(95%CI 0.53-2.02)。
- 再灌注组505例(90%)和未再灌注组1287/1595例(81%)在索引事件后启动口服抗凝。
- 两组启动口服抗凝的中位时间分别为7.5天与7.0天。
关键数值与推荐
- 主要结局为90天内卒中、短暂性脑缺血发作、症状性系统性栓塞、症状性颅内出血和主要颅外出血的复合终点。
临床怎么用
- 对于接受紧急再灌注的房颤相关缺血性卒中患者,启动口服抗凝的时机和安全性可与未再灌注患者相似管理。
局限性
- 本研究为前瞻性观察性研究合并分析,非随机对照,存在残余混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The optimal timing for starting oral anticoagulant after an ischemic stroke related to atrial fibrillation remains a challenge, mainly in patients treated with systemic thrombolysis or mechanical thrombectomy. We aimed at assessing the incidence of early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with thrombolytic therapy and/or thrombectomy, who then received oral anticoagulants for secondary prevention. METHODS: We combined the dataset of the RAF and the RAF-NOACs (Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants) studies, which were prospective observational studies carried out from January 2012 to March 2014 and April 2014 to June 2016, respectively. We included consecutive patients with acute ischemic stroke and atrial fibrillation treated with either vitamin K antagonists or nonvitamin K oral anticoagulants. Primary outcome was the composite of stroke, transient ischemic attack, symptomatic systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding within 90 days from the inclusion. Treated-patients were propensity matched to untreated-patients in a 1:1 ratio after stratification by baseline clinical features. RESULTS: A total of 2159 patients were included, 564 (26%) patients received acute reperfusion therapies. After the index event, 505 (90%) patients treated with acute reperfusion therapies and 1287 of 1595 (81%) patients untreated started oral anticoagulation. Timing of starting oral anticoagulant was similar in reperfusion-treated and untreated patients (median 7.5 versus 7.0 days, respectively). At 90 days, the primary study outcome occurred in 37 (7%) patients treated with reperfusion and in 146 (9%) untreated patients (odds ratio, 0.74 [95% CI, 0.50-1.07]). After propensity score matching, risk of primary outcome was comparable between the 2 groups (odds ratio, 1.06 [95% CI, 0.53-2.02]). CONCLUSIONS: Acute reperfusion treatment did not influence the risk of early recurrence and major bleeding in patients with atrial fibrillation-related acute ischemic stroke, who started on oral anticoagulant.
引用
- Giustozzi M, Acciarresi M, Agnelli G, et al. Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke. 2020. PMID: 32646335. doi:10.1161/STROKEAHA.120.030143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。